Literature DB >> 458556

Pharmacokinetics of digoxin: relationship between response intensity and predicted compartmental drug levels in man.

W G Kramer, A J Kolibash, R P Lewis, M S Bathala, J A Visconti, R H Reuning.   

Abstract

A study designed to investigate the relationship between the pharmacokinetics of digoxin and a measure of its pharmacological effect has been conducted. Serum digoxin concentrations and systolic time intervals were measured concurrently in 12 normal male volunteers following a 1.0 mg i.v. bolus injection. The averaged serum digoxin concentration--time and response--time data were analyzed pharmacokinetically using a three-compartment open model and nonlinear least-squares fitting. When only the serum level--time data were analyzed, a close relationship was found between calculated digoxin levels in the slowly distributing (deep) peripheral compartment and response of the heart to digoxin, as measured by changes in the QS2 index (delta QS2I). Although it was not possible to distinguish clearly a linear from a nonlinear relationship between digoxin levels in the deep compartment and delta QS2I, the nonlinear relationship gave the best overall fit when both serum digoxin and delta QS2I data were fitted simultaneously. The simultaneous fit yielded a total body clearance of digoxin of 3.6 ml/min/kg and a terminal t1/2 of 42 hr.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 458556     DOI: 10.1007/bf01059440

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  10 in total

1.  The measurement of urinary digoxin and dihydrodigoxin by radioimmunoassay and by mass spectroscopy.

Authors:  H Greenwood; W Snedden; R P Hayward; J Landon
Journal:  Clin Chim Acta       Date:  1975-07-23       Impact factor: 3.786

2.  Effect of albumin on serum digoxin radioimmunoassays.

Authors:  D L Voshall; L Hunter; H J Grady
Journal:  Clin Chem       Date:  1975-03       Impact factor: 8.327

3.  Relationship between the pharmacokinetics and pharmacodynamics of procainamide.

Authors:  R L Galeazzi; L Z Benet; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

4.  A critical review of the systolic time intervals.

Authors:  R P Lewis; S E Rittogers; W F Froester; H Boudoulas
Journal:  Circulation       Date:  1977-08       Impact factor: 29.690

5.  Specificity of the digoxin radioimmunoassay with respect to dihydrodigoxin.

Authors:  W G Kramer; M S Bathala; R H Reuning
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-05

6.  Pharmacokinetics of digoxin: comparison of a two- and a three-compartment model in man.

Authors:  W G Kramer; R P Lewis; T C Cobb; W F Forester; J A Visconti; L A Wanke; H G Boxenbaum; R H Reuning
Journal:  J Pharmacokinet Biopharm       Date:  1974-08

7.  Role of pharmacokinetics in drug dosage adjustment. I. Pharmacologic effect kinetics and apparent volume of distribution of digoxin.

Authors:  R H Reuning; R A Sams; R E Notari
Journal:  J Clin Pharmacol New Drugs       Date:  1973-04

8.  The specificity of the digoxin radioimmunoassay procedure.

Authors:  R G Stoll; M S Christensen; E Sakmar; J G Wagner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-11

9.  General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics.

Authors:  L Z Benet
Journal:  J Pharm Sci       Date:  1972-04       Impact factor: 3.534

10.  Dose-response relation between therapeutic levels of serum digoxin and systolic time intervals.

Authors:  R J Hoeschen; T E Cuddy
Journal:  Am J Cardiol       Date:  1975-04       Impact factor: 2.778

  10 in total
  31 in total

1.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

2.  Inotropic effect of digoxin in humans: mechanistic pharmacokinetic/pharmacodynamic model based on slow receptor binding.

Authors:  Michael Weiss; Wonku Kang
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

Review 3.  Rate and extent of drug accumulation after multiple dosing revisited.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

4.  Perspectives on the history and scientific contributions of Gerhard Levy.

Authors:  Ho-Leung Fung; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-24       Impact factor: 2.745

5.  An experimental design strategy for quantitating complex pharmacokinetic models: enterohepatic circulation with time-varying gallbladder emptying as an example.

Authors:  Y M Wang; R H Reuning
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

Review 6.  Pharmacokinetic-pharmacodynamic modelling: history and perspectives.

Authors:  Chantal Csajka; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-11       Impact factor: 2.745

7.  The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing.

Authors:  G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

8.  Pharmacodynamic modeling of digoxin-induced bradycardia.

Authors:  S J Vetticaden; W H Barr; T B Allison
Journal:  J Pharmacokinet Biopharm       Date:  1989-02

9.  Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.

Authors:  Yuansheng Zhao; Zhe-Yi Hu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

10.  Digoxin infusion versus bolus injection in rapid atrial fibrillation: relation between serum level and response.

Authors:  A J Smit; A H Scaf; L H van Essen; K I Lie; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.